CNS Pharmaceuticals Statistics
Total Valuation
CNSP has a market cap or net worth of $7.20 million. The enterprise value is $4.63 million.
Important Dates
The last earnings date was Thursday, May 14, 2026, before market open.
| Earnings Date | May 14, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
CNSP has 1.46 million shares outstanding. The number of shares has increased by 527.41% in one year.
| Current Share Class | 1.46M |
| Shares Outstanding | 1.46M |
| Shares Change (YoY) | +527.41% |
| Shares Change (QoQ) | +10.16% |
| Owned by Insiders (%) | 0.49% |
| Owned by Institutions (%) | 12.02% |
| Float | 1.45M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 57.73 |
| P/TBV Ratio | 103.97 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.89, with a Debt / Equity ratio of 3.29.
| Current Ratio | 0.89 |
| Quick Ratio | 0.64 |
| Debt / Equity | 3.29 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -1,098.53 |
Financial Efficiency
Return on equity (ROE) is -298.64% and return on invested capital (ROIC) is -180.95%.
| Return on Equity (ROE) | -298.64% |
| Return on Assets (ROA) | -112.92% |
| Return on Invested Capital (ROIC) | -180.95% |
| Return on Capital Employed (ROCE) | -23,511.92% |
| Weighted Average Cost of Capital (WACC) | 9.75% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$3.30M |
| Employee Count | 8 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -60.68% in the last 52 weeks. The beta is 1.03, so CNSP's price volatility has been similar to the market average.
| Beta (5Y) | 1.03 |
| 52-Week Price Change | -60.68% |
| 50-Day Moving Average | 3.81 |
| 200-Day Moving Average | 5.68 |
| Relative Strength Index (RSI) | 50.67 |
| Average Volume (20 Days) | 216,647 |
Short Selling Information
The latest short interest is 30,584, so 2.09% of the outstanding shares have been sold short.
| Short Interest | 30,584 |
| Short Previous Month | 38,968 |
| Short % of Shares Out | 2.09% |
| Short % of Float | 2.10% |
| Short Ratio (days to cover) | 0.01 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -16.62M |
| Pretax Income | -16.49M |
| Net Income | -16.49M |
| EBITDA | -16.62M |
| EBIT | -16.62M |
| Earnings Per Share (EPS) | -$29.67 |
Full Income StatementBalance Sheet
The company has $2.95 million in cash and $232,353 in debt, with a net cash position of $2.72 million or $1.86 per share.
| Cash & Cash Equivalents | 2.95M |
| Total Debt | 232,353 |
| Net Cash | 2.72M |
| Net Cash Per Share | $1.86 |
| Equity (Book Value) | 70,705 |
| Book Value Per Share | 0.09 |
| Working Capital | -504,148 |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$15.22 million and capital expenditures -$24,354, giving a free cash flow of -$15.24 million.
| Operating Cash Flow | -15.22M |
| Capital Expenditures | -24,354 |
| Depreciation & Amortization | 4,686 |
| Net Borrowing | -306,889 |
| Free Cash Flow | -15.24M |
| FCF Per Share | -$10.43 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
